Depot‐medroxyprogesterone acetate (DMPA) and risk of liver cancer

THE WHO COLLABORATIVE STUDY OF NEOPLASIA AND STEROID CONTRACEPTIVES

Research output: Contribution to journalArticlepeer-review

Abstract

A hospital‐based case‐control study was conducted to assess the possible relationship between use of depot‐medroxy‐progesterone acetate (DMPA), an injectable progestational contraceptive, and the development of liver cancer in 2 developing countries where hepatitis B is endemic. Information about prior DMPA use and potential confounders was ascertained during personal interviews with 71 cases and 530 controls from 3 hospitals in Thailand and 1 hospital in Kenya. No significant association between liver cancer and DMPA use was observed in Kenya (RR = 1.64, 95% CI = 0.4‐0.6) or Thailand (RR = 0.33, 95% CI = 0.1‐1.O). No consistent changes in risk were observed with duration of use, time since last use, or time since first use. No significant associations were observed between DMPA use and risks of either hepatocellular carcinoma or cholangiocarcinoma. These findings suggest that risk of liver cancer in areas where hepatitis B is endemic is not appreciably altered by the use of DMPA.

Original languageEnglish (US)
Pages (from-to)182-185
Number of pages4
JournalInternational Journal of Cancer
Volume49
Issue number2
DOIs
StatePublished - Sep 9 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Depot‐medroxyprogesterone acetate (DMPA) and risk of liver cancer'. Together they form a unique fingerprint.

Cite this